Market Outlook

By 2035, the U.S. Age-Related Macular Degeneration Diagnostic Devices Market is expected to reach approximately USD 1.74 billion, expanding at a CAGR of 10.90% during the forecast period 2026–2035. The market is estimated at USD 0.62 billion in 2025, with historical analysis covering 2021–2024. Market values in this report are expressed in USD billions.

The historical market expanded from approximately USD 0.40 billion in 2021 to USD 0.55 billion in 2024, supported by recovery in ophthalmology visit volumes, continued replacement of conventional retinal cameras with multimodal imaging systems, widening use of spectral-domain and swept-source optical coherence tomography, increased treatment-monitoring intensity in neovascular age-related macular degeneration, and greater adoption of imaging-based assessment for geographic atrophy.

The market is expected to reach approximately USD 0.69 billion in 2026, USD 1.04 billion by 2030, and USD 1.74 billion by 2035. The growth trajectory is materially stronger than that of conventional ophthalmic diagnostic equipment because AMD increasingly requires longitudinal, image-intensive management rather than a single diagnostic encounter.

Age-related macular degeneration represents one of the most important retinal diseases affecting older Americans. U.S. public-health surveillance has estimated that approximately 19.8 million Americans aged 40 years and older were living with AMD, including approximately 1.49 million with vision-threatening disease. Disease prevalence rises sharply with age and approaches almost half of individuals aged 85 years and older in available population estimates. This demographic relationship makes AMD diagnostics structurally exposed to U.S. population aging.

The addressable clinical workflow is also expanding. The U.S. population aged 65 years and older exceeded 61 million in 2024, representing approximately 18% of the population, while Medicare enrollment surpassed 70 million beneficiaries during 2026. These demographics create a large reimbursed patient population requiring repeated retinal examination, OCT imaging, progression assessment, treatment-response evaluation, and long-term surveillance.

This report defines the U.S. Age-Related Macular Degeneration Diagnostic Devices Market as device and device-linked technology revenue attributable to the identification, characterization, staging, differential diagnosis, and monitoring of dry AMD, geographic atrophy, and neovascular AMD. The scope primarily includes optical coherence tomography systems, OCT angiography platforms, fundus and retinal cameras, ultra-widefield imaging systems, fundus autofluorescence platforms, fluorescein and indocyanine green angiography-capable systems, home OCT and home-monitoring devices, and AI-enabled diagnostic functions commercialized as part of imaging-device workflows.

The strategic center of the market is shifting from simply obtaining a retinal image toward generating longitudinal information that can guide clinical decision-making. Retina practices increasingly value platforms that identify intraretinal fluid, subretinal fluid, pigment epithelial changes, drusen, atrophy progression, macular neovascularization, and treatment-response patterns with reproducible measurements. Consequently, image acquisition speed, segmentation reliability, multimodal registration, workflow automation, cloud connectivity, and longitudinal comparison are becoming as important commercially as optical resolution.

Hospital and retina-practice procurement is therefore moving toward platform economics. A premium diagnostic system can increasingly justify its capital cost when it reduces technician time, lowers repeat scans, enables higher daily patient throughput, integrates multiple imaging modalities, supports treatment decisions, and produces consistent longitudinal data across physicians and locations. These economics will support premiumization of the market through 2035.

 

Introduction

According to the U.S. Age-Related Macular Degeneration Diagnostic Devices Market Report, AMD diagnostics is evolving into one of the most strategically important areas of U.S. retinal imaging because the disease combines a large aging patient pool with recurring diagnostic requirements and high consequences for delayed identification of disease progression.

AMD affects the macula and can impair central vision required for reading, driving, facial recognition, and other high-value daily activities. Early-stage disease may be asymptomatic, while progression toward geographic atrophy or neovascular AMD can create substantial irreversible visual impairment. For this reason, U.S. clinical management increasingly relies on imaging before patients experience major functional deterioration.

The diagnostic pathway typically begins with clinical examination and retinal visualization but increasingly progresses to high-resolution OCT for structural evaluation. OCT can identify retinal fluid, drusen, pigment epithelial detachments, retinal thinning, outer-retinal disruption, and other biomarkers that influence AMD classification and follow-up. OCT angiography can provide non-invasive visualization of retinal and choroidal vascular flow, while fluorescein angiography, indocyanine green angiography, fundus autofluorescence, color photography, and ultra-widefield imaging provide complementary information in selected cases.

The market should therefore not be viewed as a collection of isolated imaging machines. Leading retina practices increasingly operate multimodal diagnostic ecosystems where OCT, OCTA, photography, angiography, autofluorescence, image-management software, and clinical records work together. The commercial value of a vendor increasingly depends on how effectively its platform reduces workflow fragmentation.

Treatment innovation is simultaneously raising the value of diagnostics. Patients with neovascular AMD may undergo repeated anti-VEGF therapy and require imaging to assess fluid recurrence and treatment response. Geographic atrophy has also become a more actively managed clinical category following the emergence of approved therapies, increasing the need to identify appropriate patients and document anatomical progression. The diagnostic market therefore benefits from treatment innovation even though pharmaceutical revenues are excluded from this report.

Population aging provides a durable structural growth base. The prevalence of AMD rises steeply with age, and U.S. Census projections show continued expansion in the older population. By 2030, all members of the baby-boom generation will be older than 65. This matters because AMD diagnostic utilization is concentrated among Medicare-age patients and therefore has a demographic growth profile that is more favorable than many general ophthalmic diagnostic categories.

A second structural advantage is the recurring nature of AMD imaging. A patient may undergo multiple OCT examinations each year, particularly when receiving active treatment or being closely observed for progression. This creates demand not only for new equipment but for replacement systems, software upgrades, service agreements, image-management infrastructure, additional scanners in high-throughput practices, and potentially home-monitoring capacity.

The clinical setting is also changing. Academic retina centers remain critical adopters of advanced OCTA, multimodal imaging, quantitative autofluorescence, research-grade image analysis, and novel biomarkers. However, much of U.S. AMD care is delivered through community retina practices and multispecialty ophthalmology groups. Vendors that can deliver specialist-grade imaging with simplified acquisition, automated alignment, compact footprints, and predictable ownership economics can therefore expand beyond tertiary centers.

The resulting market is attractive not simply because more AMD patients are being diagnosed. It is attractive because each patient is becoming more imaging-intensive, diagnostic platforms are becoming more sophisticated, and U.S. retina practices increasingly depend on objective imaging biomarkers to manage treatment intervals and disease progression.

 

Key Market Drivers: What’s Fueling the U.S. Age-Related Macular Degeneration Diagnostic Devices Market Boom?

The most powerful market driver is the scale of the underlying AMD population. Approximately 19.8 million Americans aged 40 years and older were estimated to have some form of AMD in population-based surveillance, while approximately 1.49 million had vision-threatening AMD. Prevalence rises from low single-digit percentages among adults in their early forties to more than 40% among the oldest age groups. As the U.S. population ages, the number of patients requiring retinal screening, confirmation, differential diagnosis, and follow-up is expected to expand.

A second driver is the increasing clinical dependence on OCT. Structural OCT has become central to retina workflow because it provides high-resolution cross-sectional information that cannot be obtained from standard fundus examination alone. OCT is particularly valuable in neovascular AMD because fluid status strongly influences treatment assessment. Repeated scanning converts OCT from a one-time diagnostic technology into a high-frequency disease-management platform.

A third driver is the transition toward multimodal retinal imaging. AMD is biologically heterogeneous, and no single modality captures all relevant anatomical and vascular information. OCT can characterize retinal layers and fluid; OCT angiography can visualize vascular networks without dye; fluorescein and indocyanine green angiography can support vascular characterization; autofluorescence can help evaluate retinal pigment epithelium-related changes; and color or ultra-widefield imaging can document broader retinal findings. Platforms capable of combining several modalities can command higher value because they reduce patient movement between devices and consolidate diagnostic data.

Geographic atrophy is an important incremental demand driver. Historically, many patients with advanced dry AMD had limited interventional options, reducing the commercial intensity of longitudinal imaging compared with actively treated neovascular disease. The arrival of therapies for geographic atrophy changes this dynamic. Retina specialists increasingly need to document lesion characteristics, progression, patient eligibility, and treatment response, supporting greater use of OCT, autofluorescence, and multimodal imaging.

A fifth driver is growing pressure on retina-practice capacity. AMD predominantly affects older patients who may require frequent visits, creating congestion in high-volume practices. Imaging platforms that reduce acquisition time, automate alignment, minimize rescans, and generate standardized longitudinal comparisons can improve patient throughput. Procurement decisions are therefore increasingly based on technician productivity and chair-time economics rather than image resolution alone.

Home monitoring represents another structural growth catalyst. In 2024, the U.S. FDA granted De Novo authorization to a home OCT system designed for patients with neovascular AMD. The development is strategically significant because it establishes a regulatory precedent for imaging patients between regularly scheduled office assessments. Home OCT does not replace specialist examination, but it introduces a potentially new diagnostic-delivery model in which retinal disease activity can be visualized more frequently without requiring every data point to originate inside the clinic.

AI-enabled image analysis is also strengthening the market. Retina clinics generate large numbers of OCT B-scans and longitudinal datasets. Algorithms that prioritize abnormal scans, quantify retinal fluid, identify structural biomarkers, segment anatomical layers, compare progression, or reduce image-review burden can increase the economic value of the underlying device platform. Over time, AI may become less of a separately purchased feature and more of an expected element of premium retinal imaging systems.

Finally, U.S. reimbursement infrastructure supports recurring retinal imaging. OCT is deeply embedded within ophthalmology practice patterns, including Medicare-supported retinal disease management. Although coverage policies, medical-necessity requirements, frequency controls, and commercial payer rules vary, reimbursement reduces the economic barrier to clinically appropriate imaging and supports continued investment in high-utilization platforms.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in AMD diagnostic devices is increasingly centered on three priorities: detecting biologically meaningful changes earlier, acquiring information with less workflow burden, and converting images into quantitative longitudinal evidence.

Swept-source OCT is an important technology direction. Compared with conventional spectral-domain systems, swept-source platforms can offer higher scan speeds, deeper penetration, wider fields, and improved visualization through selected media opacities. These capabilities are particularly relevant for elderly AMD patients, many of whom may also have cataract, pseudophakia, or other age-related ocular findings.

OCT angiography is moving from a specialized research or tertiary-center modality toward broader clinical use. OCTA provides non-invasive visualization of vascular flow and can help characterize macular neovascularization without requiring dye injection. Its value proposition strengthens when acquisition becomes faster, artifact correction improves, and vessel visualization is automatically registered with structural OCT.

Fundus autofluorescence is becoming more strategically important in dry AMD and geographic atrophy. Autofluorescence provides information related to retinal pigment epithelial health and can complement structural OCT when clinicians characterize atrophic lesions. As geographic atrophy moves into an actively treated disease-management pathway, multimodal platforms integrating OCT and autofluorescence may gain disproportionate procurement attention.

Ultra-widefield imaging is also expanding the retinal information available during a single encounter. AMD is centered on the macula, but elderly patients frequently present with additional retinal pathology. Wider-field visualization can help providers assess broader disease while reducing the need for separate imaging sessions. Platforms combining ultra-widefield photography with OCT, angiography, or autofluorescence can strengthen equipment utilization across multiple retinal indications and therefore improve capital return.

Home OCT represents one of the most disruptive innovations in the market. A home system authorized for neovascular AMD allows selected patients to perform repeated retinal imaging outside the clinic, with data transmitted for analysis and physician review. Pivotal studies have demonstrated that elderly patients can successfully acquire images at home at high rates. Commercial adoption will depend on patient selection, reimbursement, integration into retina-practice workflows, alert management, and evidence that additional imaging information changes care in an economically sustainable way.

AI is becoming embedded in image acquisition and interpretation. Current development is moving beyond simple image enhancement toward automated pathology localization, scan-quality assessment, fluid segmentation, abnormality detection, volumetric analysis, and progression comparison. The highest-value applications will be those that reduce physician review time while remaining clinically interpretable and consistent across repeat examinations.

Cloud-based longitudinal image management is another area of competitive differentiation. Large retina groups frequently operate across multiple locations and may use different equipment generations. Vendors that allow historical scans to be retrieved, compared, quantified, and shared across locations can become embedded in the clinical workflow. This creates switching costs beyond the physical hardware itself.

Manufacturers are also improving scan speed. Faster OCT and OCTA acquisition can be economically important because small reductions in technician time become material when multiplied across thousands of annual examinations. Recent imaging-system upgrades have pushed OCT angiography scanning toward substantially higher acquisition rates, while advanced eye-tracking systems can improve registration and reduce motion-related rescanning.

The competitive frontier is therefore moving from “better images” toward “better retinal intelligence.” The winning systems through 2035 will likely be those that combine high-resolution imaging, multimodal information, automated analytics, longitudinal comparison, scalable data infrastructure, and workflow economics appropriate for both tertiary centers and high-volume community retina practices.

 

Segmentation Insights

The U.S. Age-Related Macular Degeneration Diagnostic Devices Market is segmented on the basis of product type, diagnostic application, end user, technology type, and geography.

 

By Product Type

Optical Coherence Tomography Systems

Optical coherence tomography systems represent the largest product category in the U.S. AMD diagnostic devices market. Their position is supported by the central role of OCT in detecting and monitoring intraretinal fluid, subretinal fluid, pigment epithelial detachments, drusen, retinal thinning, and other structural abnormalities associated with AMD. OCT is particularly indispensable in neovascular AMD follow-up, where repeated imaging can influence treatment-interval decisions. Replacement demand is increasingly shifting toward higher-speed systems, swept-source technology, improved segmentation, automated follow-up registration, and integrated OCTA.

Fundus and Retinal Cameras

Fundus and retinal cameras provide color documentation of macular changes and remain relevant across screening, baseline documentation, patient education, referral, and longitudinal disease assessment. Non-mydriatic and automated platforms can improve throughput, while portable systems can expand access outside conventional retina clinics. Their AMD-specific revenue share is lower than OCT but remains material because fundus photography frequently forms part of broader retinal diagnostic workups.

Ultra-Widefield and Multimodal Imaging Systems

Ultra-widefield and integrated multimodal platforms are one of the higher-value product categories. Premium systems may combine color retinal imaging, autofluorescence, OCT, angiography, and other modalities within a single workflow. The commercial attraction is not limited to AMD: retina practices can use the same platform across diabetic retinopathy, retinal vascular disease, inflammatory disease, peripheral retinal pathology, and other conditions. This multi-indication utilization improves capital economics and supports premium purchasing.

Angiography and Autofluorescence Systems

Fluorescein angiography, indocyanine green angiography, and fundus autofluorescence remain clinically relevant when structural OCT alone does not provide sufficient information. Angiography can help characterize vascular leakage and neovascular lesions, while autofluorescence is particularly relevant for retinal pigment epithelium abnormalities and geographic atrophy evaluation. Integration of these modalities into broader retinal platforms is gradually reducing the market for single-purpose systems.

Home Monitoring and Home OCT Devices

Home-monitoring systems represent the smallest current revenue category but are expected to record the fastest percentage growth. The commercial opportunity is concentrated initially in selected neovascular AMD populations where disease activity can change between scheduled visits. FDA authorization of home OCT established a meaningful U.S. regulatory precedent, and future expansion could create recurring equipment, service, connectivity, and monitoring revenue rather than conventional one-time capital sales.

 

By Diagnostic Application

Early Detection and Risk Stratification

Early detection includes identification of drusen, pigmentary changes, structural abnormalities, and other findings that indicate AMD before severe vision loss occurs. Because early-stage AMD may not produce symptoms, regular imaging of at-risk older adults can support earlier referral and disease characterization. Automated fundus imaging and increasingly accessible OCT may expand this application in comprehensive ophthalmology and optometry settings.

Dry AMD and Geographic Atrophy Assessment

Dry AMD represents the largest patient population, while geographic atrophy accounts for an increasingly important high-value diagnostic subset. OCT, autofluorescence, color imaging, and multimodal systems are used to assess lesion morphology and progression. The emergence of geographic atrophy treatment has increased the clinical value of objective longitudinal documentation and may drive more standardized imaging protocols.

Neovascular AMD Diagnosis

Neovascular or wet AMD is a smaller patient population than dry AMD but generates substantially higher diagnostic intensity. OCT is used to identify retinal and subretinal fluid, while OCTA, fluorescein angiography, and indocyanine green angiography may support characterization of macular neovascularization. Because delayed treatment can result in irreversible visual loss, diagnostic speed and access are commercially important.

Treatment-Response Monitoring

Treatment monitoring is one of the most economically attractive applications because imaging is repeated over time. Patients receiving intravitreal therapy may undergo OCT during treatment visits to assess disease activity and determine whether intervals should be maintained, shortened, or extended. This recurring utilization supports high equipment productivity and strengthens the replacement case for faster systems.

Disease Progression and Longitudinal Surveillance

Longitudinal surveillance includes follow-up of intermediate AMD, fellow-eye monitoring, post-treatment assessment, geographic atrophy progression, and remote or home-based monitoring. This segment is expected to gain share because diagnostic strategy is moving from episodic imaging toward continuous disease-state evaluation.

 

By End User

Retina Specialty Practices

Retina specialty practices represent the largest and most commercially influential end-user segment. These practices manage high volumes of neovascular AMD, geographic atrophy, diabetic retinopathy, retinal vascular disease, and other posterior-segment conditions. High scanner utilization allows premium OCT and multimodal imaging platforms to generate strong economic returns. Large retina groups increasingly standardize devices across multiple sites and assess procurement based on workflow, service support, data interoperability, and total ownership cost.

Hospitals and Health Systems

Hospitals and integrated health systems represent an important end-user group, particularly academic medical centers and tertiary referral hospitals. These facilities often purchase advanced multimodal systems for complex cases, clinical trials, fellowship training, and research. Hospital value-analysis committees typically require stronger capital justification than independent practices, favoring platforms that serve multiple ophthalmic indications and integrate with enterprise IT environments.

Ophthalmology Clinics

General and multispecialty ophthalmology clinics are an important growth segment because many AMD patients are first detected outside dedicated retina practices. OCT has increasingly become a core diagnostic tool within comprehensive ophthalmology. Clinics may prefer automated systems with smaller footprints, simplified image acquisition, lower training requirements, and connectivity that facilitates referral to retina specialists.

Optometry and Vision-Care Practices

Optometry practices represent an emerging early-detection channel. Advanced retinal cameras and OCT systems allow optometrists to identify suspicious macular changes and refer patients for ophthalmic evaluation. Adoption is sensitive to device cost, reimbursement, practice volume, and ease of interpretation. AI-supported triage could increase this segment’s relevance over the forecast period.

Home and Remote Monitoring

Home use represents a nascent but strategically important end-user environment. The economic model differs fundamentally from conventional capital equipment because deployment may involve monitoring services, cloud infrastructure, physician dashboards, device logistics, and recurring patient engagement. Adoption will depend on demonstrated clinical benefit and manageable workflow integration for retina specialists.

 

By Technology Type

Spectral-Domain OCT

Spectral-domain OCT remains the installed-base standard across U.S. ophthalmology and retina practices. It provides high-resolution retinal cross-sectional imaging at commercially practical cost and supports established diagnostic protocols. The large installed base creates substantial replacement and software-upgrade opportunities through 2035.

Swept-Source OCT

Swept-source OCT represents a higher-growth technology class because it supports fast scanning, deep penetration, broad fields, and advanced multimodal applications. Premium retina centers and high-volume practices are likely to account for early adoption, followed by broader penetration as equipment economics improve.

OCT Angiography

OCT angiography is expected to gain utilization as acquisition speed, motion correction, segmentation, and image interpretation improve. Its non-invasive nature is attractive in elderly populations because it can provide vascular information without dye injection. OCTA will increasingly be purchased as an integrated capability rather than a standalone technology.

Retinal Photography, Angiography and Autofluorescence

This technology category includes conventional and ultra-widefield color imaging, fluorescein angiography, indocyanine green angiography, and fundus autofluorescence. The major competitive shift is toward integrated multimodal systems that can perform several functions during one patient encounter.

AI-Enabled and Connected Diagnostic Technology

AI-enabled devices, cloud-connected imaging, automated segmentation, remote monitoring, quantitative progression analysis, and device-integrated decision-support tools are expected to record the highest strategic growth. AI will increasingly influence equipment selection because its value is tied to throughput, standardization, review burden, and longitudinal data management rather than image acquisition alone.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Age-Related Macular Degeneration Diagnostic Devices Market is geographically divided into the South, Northeast, West, and Midwest. Regional performance differs according to elderly-population concentration, ophthalmologist and retina-specialist density, Medicare enrollment, presence of academic retinal centers, health-system capital investment, prevalence of AMD risk factors, penetration of premium diagnostic technologies, and access to specialized retinal care.

The South is the largest regional market in 2025, while the West is expected to record the fastest growth through 2035. The Northeast remains the most specialist-intensive and academically influential region, and the Midwest provides a stable base of high-volume retinal care supported by mature regional health systems.

South

The South represents an estimated USD 0.22 billion in 2025 and is projected to reach approximately USD 0.64 billion by 2035, reflecting an estimated regional CAGR of approximately 11.2%. The region’s leadership is driven by population scale, large Medicare enrollment, substantial numbers of older residents, migration into retirement-oriented states, major ophthalmology networks, and expanding retina-practice infrastructure.

Florida is the most important AMD diagnostic market in the South. Public-health estimates have previously placed Florida at the high end of state-level AMD prevalence, with crude prevalence estimated at 18.3% in the modeled population. The state combines a large retirement-age population with dense ophthalmology and retina-service networks in Miami, Fort Lauderdale, West Palm Beach, Tampa, Orlando, Jacksonville, Naples, Sarasota, and other metropolitan areas. High treatment volumes support substantial recurring OCT utilization and create attractive economics for advanced multimodal imaging.

Texas represents another major market because of its population size and extensive medical infrastructure. Houston, Dallas-Fort Worth, Austin, San Antonio, and major academic health systems create significant demand for OCT, OCTA, angiography, and retinal photography. The state combines sophisticated tertiary retina programs with broad rural geographies, creating opportunities for both premium imaging and more distributed diagnostic models.

North Carolina benefits from leading academic centers and expanding health-system networks, while South Carolina has increasing ophthalmic demand associated with population growth and retirement migration. Georgia is anchored by Atlanta’s large specialist market but also presents access gaps outside major urban areas. Tennessee has strong regional referral centers in Nashville, Memphis, Knoxville, and Chattanooga.

Virginia and Maryland combine affluent metropolitan markets, academic medical centers, strong Medicare populations, and proximity to federal research infrastructure. Delaware is smaller in absolute revenue but has an older age profile that supports AMD diagnostic demand. West Virginia presents a smaller market with substantial access challenges, making referral networks and efficient imaging workflows particularly important.

Kentucky, Alabama, Mississippi, Louisiana, Arkansas, and Oklahoma represent smaller device markets individually but collectively create meaningful demand. These states have lower specialist density outside metropolitan areas, increasing the value of efficient referral pathways, automated imaging, teleophthalmology-enabled review, and devices capable of supporting broader retinal diagnosis.

The South also includes the District of Columbia in certain healthcare market frameworks, although it is generally analyzed separately from state markets. Washington, D.C. has unusually high academic and specialty-care intensity despite a relatively low crude AMD prevalence compared with older states.

Overall, the South offers the strongest absolute expansion opportunity because population growth and aging are occurring simultaneously. Manufacturers that combine premium retina-center platforms with scalable offerings for community ophthalmology will be better positioned than vendors focused only on top-tier academic institutions.

West

The West represents an estimated USD 0.14 billion in 2025 and is projected to reach approximately USD 0.42 billion by 2035, corresponding to an estimated CAGR of approximately 11.7%, the fastest among the four regions.

California dominates the western market. Its scale, large Medicare population, extensive academic ophthalmology network, strong integrated delivery systems, and technology-oriented provider base make it an important launch environment for AI-enabled diagnostics, advanced OCT, remote monitoring, and multimodal retinal imaging. Los Angeles, San Francisco Bay Area, San Diego, Sacramento, and Orange County support significant specialist demand.

Arizona is particularly attractive because of rapid population growth and a large retirement community. Phoenix, Scottsdale, Tucson, and surrounding markets support growing retina-care capacity. Nevada has similar demographic characteristics, with Las Vegas and Reno accounting for a substantial share of specialist demand.

Washington and Oregon have sophisticated health systems and comparatively strong adoption of connected healthcare technologies. Large systems in Seattle, Portland, and surrounding metropolitan areas provide attractive environments for centralized image management and enterprise diagnostic platforms.

Colorado and Utah combine growing populations with research-oriented health systems and expanding specialty-care capacity. Denver and Salt Lake City function as referral hubs extending into adjacent rural states, strengthening the value of high-throughput retinal imaging and telehealth-compatible diagnostic workflows.

New Mexico faces more pronounced geographic access challenges, increasing the potential role of portable retinal imaging and referral-enabling technologies. Idaho is experiencing population growth that is creating demand for expanded ophthalmic capacity.

Montana and Wyoming are smaller markets but have large rural catchment areas, making specialist access a structural constraint. Alaska faces even greater geographic barriers and may benefit disproportionately from connected imaging and remote interpretation models. Hawaii has a relatively small absolute market but an older population and geographic concentration of specialist care on selected islands.

The West is strategically important because adoption of digital health, AI-supported imaging, cloud infrastructure, and remote care tends to occur relatively early in major western provider systems. This should allow the region to gain market share through 2035 despite having a smaller 2025 revenue base than the South.

Northeast

The Northeast represents approximately USD 0.15 billion in 2025 and is expected to reach around USD 0.40 billion by 2035, corresponding to an estimated CAGR of approximately 10.4%.

New York represents the largest state market in the region. New York City has an exceptionally high concentration of ophthalmologists, academic hospitals, retinal specialists, research centers, and high-acuity patients. Upstate markets including Buffalo, Rochester, Syracuse, and Albany provide additional regional referral demand.

Massachusetts is disproportionately influential relative to population because Boston is a major center for ophthalmic clinical research, retina specialization, medical technology development, and academic medicine. New diagnostic technologies can achieve important clinical validation and opinion-leader exposure in this market even when absolute device volumes are below those of California, Florida, or Texas.

Pennsylvania provides a large patient base across Philadelphia, Pittsburgh, and regional health systems. The state combines large academic centers with community ophthalmology networks and a meaningful older population. New Jersey benefits from high population density, proximity to New York and Philadelphia, strong insurance coverage, and extensive specialist practices.

Connecticut and Rhode Island are smaller but comparatively dense healthcare markets in which high-value imaging platforms can be utilized across affluent, Medicare-heavy patient populations. New Hampshire, Vermont, and Maine have smaller absolute revenue potential but older demographic profiles that create substantial AMD need relative to population size.

The Northeast is likely to remain one of the highest-value regions per specialist site because clinicians and institutions frequently adopt premium imaging configurations. However, slower population growth and already-high technology penetration will cause percentage growth to trail the West and South.

Midwest

The Midwest represents approximately USD 0.11 billion in 2025 and is projected to reach approximately USD 0.28 billion by 2035, corresponding to an estimated CAGR of approximately 9.7%.

Illinois is the largest Midwestern opportunity, led by Chicago’s major academic, integrated health-system, and independent ophthalmology networks. Ohio has a strong specialty-care infrastructure across Cleveland, Columbus, Cincinnati, and other metropolitan areas, while Michigan supports significant retina demand in Detroit, Ann Arbor, Grand Rapids, and surrounding markets.

Minnesota is strategically relevant because of its advanced health systems and broader medical-device ecosystem. Wisconsin has mature regional provider networks and a substantial older population supporting stable OCT demand.

Indiana and Missouri provide sizable community ophthalmology and hospital markets centered on Indianapolis, St. Louis, Kansas City, and other population centers. Iowa, Kansas, and Nebraska operate through strong regional referral patterns in which large ophthalmology groups may serve geographically dispersed patient populations.

North Dakota and South Dakota are relatively small markets in revenue terms but illustrate the access challenge facing rural AMD patients. Long travel distances can make repeat retinal assessments burdensome. Portable imaging, remote interpretation, and eventually home-monitoring approaches could therefore produce higher strategic value than absolute market size might suggest.

The Midwest is not expected to grow as rapidly as the South or West, but it remains attractive because of stable procedure volumes, established ophthalmology practices, major academic centers, and substantial replacement demand for existing OCT systems.

 

Key Market Players

The U.S. Age-Related Macular Degeneration Diagnostic Devices Competitive Landscape is moderately concentrated in premium OCT and multimodal retinal imaging, while remaining fragmented across portable imaging, AI, home monitoring, and specialty diagnostic technologies.

Competition increasingly centers on complete retina workflows rather than individual instruments. Manufacturers are differentiating themselves through scan speed, optical resolution, swept-source capability, OCT angiography, fundus autofluorescence, ultra-widefield imaging, multimodal registration, automated follow-up, AI-enabled analysis, interoperability, service reliability, and installed-base software integration.

Some of the key players relevant to the U.S. Age-Related Macular Degeneration Diagnostic Devices industry include Carl Zeiss Meditec AG, Heidelberg Engineering GmbH, Topcon Healthcare, Optos plc/Nikon Corporation, NIDEK CO., LTD., Canon Inc., Kowa Company Ltd., Optomed Plc, Revenio Group/iCare, Haag-Streit Group, Visionix, Tomey Corporation, Notal Vision, Eyenuk Inc., Remidio Innovative Solutions, Intalight, MicroClear Medical, OcuSciences Inc., Alcon Inc., Bausch + Lomb Corporation, Essilor Instruments, Phoenix Technology Group, and Clarity Medical Systems.

Carl Zeiss Meditec, Heidelberg Engineering, Topcon, Optos, and NIDEK form the strongest competitive group in premium retinal imaging because of their established ophthalmic installed bases and broad diagnostic portfolios. These companies benefit from longstanding relationships with retina specialists, integrated imaging software, extensive clinical literature, service infrastructure, and high switching costs once practices standardize longitudinal imaging workflows.

ZEISS competes through the CIRRUS OCT family, CLARUS retinal imaging platform, integrated ophthalmic software, OCT angiography, and emerging AI-enabled workflow capabilities. The company is particularly strong where health systems value integration across diagnostic and surgical ophthalmology.

Heidelberg Engineering has a strong reputation in high-resolution multimodal imaging through the SPECTRALIS platform. Its competitive advantage is particularly relevant in retina practices and academic centers that prioritize repeatability, active eye tracking, OCTA, autofluorescence, angiography, and multimodal image registration.

Topcon Healthcare competes through broad OCT and multimodal imaging portfolios, including swept-source technology. Automated acquisition and workflow-oriented systems are relevant to both specialist retina environments and comprehensive ophthalmology practices seeking easier deployment.

Optos differentiates through ultra-widefield retinal imaging. Its ability to combine extremely wide retinal visualization with OCT, autofluorescence, angiography, and other modalities strengthens its position in high-volume retina practices seeking consolidated diagnostic workflows.

NIDEK participates through OCT, scanning laser ophthalmoscopy, multimodal retinal imaging, and angiography technologies. Canon and Kowa retain relevance in retinal photography and specialist ophthalmic imaging, while Optomed, Remidio, and other portable-imaging developers address growing demand for flexible retinal-image acquisition.

Notal Vision represents one of the most strategically differentiated participants because it is building a home-based diagnostic model rather than competing solely for space inside the ophthalmology clinic. FDA authorization of its home OCT system creates an opportunity to establish a new recurring monitoring category around neovascular AMD.

AI-focused companies such as Eyenuk and emerging analytics providers are likely to influence competitive positioning even when they do not generate the majority of hardware revenue. Device manufacturers increasingly need either proprietary analytics or integration partnerships to prevent their imaging platforms from becoming commoditized acquisition tools.

Over the forecast period, market share will increasingly depend on the ability to demonstrate measurable improvements in clinical workflow. The most defensible premium positioning will belong to vendors that can document faster acquisition, lower rescan rates, quantitative biomarker analysis, reliable longitudinal registration, reduced physician review burden, and interoperability across large multi-location retina practices.

 

Recent Developments

Recent developments indicate that the U.S. AMD diagnostic devices market is entering a new innovation cycle characterized by home imaging, faster OCT angiography, multimodal integration, and AI-assisted retinal assessment.

In May 2024, the FDA granted De Novo marketing authorization for the Notal Vision Home OCT System. The authorization established a new Class II category for home-monitoring ophthalmic OCT imaging devices. The system is designed for patients diagnosed with neovascular AMD and allows retinal OCT images to be captured between scheduled clinical assessments. This represents a significant change in the traditional retina-care model because advanced imaging can now extend into the patient’s home.

Clinical data released during 2025 continued to evaluate home OCT usability and diagnostic performance. Studies involving older neovascular AMD populations demonstrated that large majorities of participants were capable of successfully acquiring retinal scans at home. These findings are commercially important because usability among older adults is one of the major constraints on home diagnostic adoption.

In February 2025, Optos introduced MonacoPro, advancing the company’s integrated ultra-widefield and spectral-domain OCT platform. The development reflects a broader industry trend toward consolidation of retinal imaging modalities within one workflow rather than reliance on separate single-purpose devices.

During October 2025, Optos announced Silverstone RGB, combining 200-degree single-shot retinal color imaging with swept-source OCT and multiple additional retinal imaging modalities. Such platforms illustrate how the premium retina market is evolving toward broad anatomical coverage and multimodal assessment from a single system.

In 2025, NIDEK highlighted enhancements in OCT angiography resolution within its retinal-imaging portfolio at the American Academy of Ophthalmology meeting in Orlando. Continued algorithm and acquisition improvements across the industry are reducing the historical gap between OCTA’s clinical potential and routine workflow practicality.

In June 2026, Heidelberg Engineering announced FDA clearance for an updated SPECTRALIS software release incorporating OCT angiography scanning speeds of up to 250 kHz, enhanced active eye tracking, and additional multimodal capabilities including green autofluorescence. Commercial availability followed during 2026. The development demonstrates that software and scanning architecture upgrades can materially extend the commercial life of installed imaging platforms.

AI-enabled retinal image interpretation is also progressing rapidly. Manufacturers are developing algorithms capable of identifying abnormal macular OCT scans, enhancing OCTA images, improving segmentation, quantifying retinal fluid, and reducing the number of images physicians must inspect manually. Regulatory status varies by product and jurisdiction, but the direction of competition is clear: automation is becoming a central feature of next-generation ophthalmic imaging.

The market is consequently moving into a period in which hardware innovation and software innovation are increasingly inseparable. Future purchasing decisions will be influenced not only by optical specifications but by how effectively a system converts raw imaging data into clinically actionable longitudinal information.

 

Conclusion

The U.S. Age-Related Macular Degeneration Diagnostic Devices Market Size & Share is positioned for strong expansion from approximately USD 0.62 billion in 2025 to USD 1.74 billion by 2035, representing a 10.90% CAGR during 2026–2035.

The historical market expanded from approximately USD 0.40 billion in 2021 to USD 0.44 billion in 2022, USD 0.49 billion in 2023, USD 0.55 billion in 2024, and USD 0.62 billion in 2025. Forecast revenues are expected to progress to approximately USD 0.69 billion in 2026, USD 0.76 billion in 2027, USD 0.85 billion in 2028, USD 0.94 billion in 2029, USD 1.04 billion in 2030, USD 1.15 billion in 2031, USD 1.28 billion in 2032, USD 1.42 billion in 2033, USD 1.57 billion in 2034, and USD 1.74 billion in 2035.

The most durable market driver is demographic. AMD prevalence rises sharply with age, while the U.S. population aged 65 years and older already exceeds 61 million. This provides a growing base of patients requiring retinal assessment and long-term surveillance.

However, demographics alone do not explain the forecast growth rate. Revenue expansion will increasingly be generated by greater diagnostic intensity per patient. Neovascular AMD requires repeated OCT assessment; geographic atrophy is moving into a more active treatment and monitoring environment; OCTA is extending vascular imaging capabilities; multimodal systems are replacing fragmented workflows; AI is increasing the amount of quantitative information generated per scan; and home OCT is creating a new potential location of care.

Optical coherence tomography will remain the economic foundation of the market, but the competitive definition of OCT will broaden. Premium platforms will increasingly include OCTA, widefield acquisition, autofluorescence, angiography, advanced eye tracking, automated segmentation, cloud connectivity, and AI-supported analysis.

Retina specialty practices will remain the largest end-user segment because they combine high AMD patient volumes with frequent imaging and strong clinical dependence on objective retinal biomarkers. Comprehensive ophthalmology practices will become increasingly important as OCT becomes standard infrastructure for identifying and referring retinal disease. Home-monitoring models represent the most disruptive longer-term end-user opportunity.

Geographically, the South is expected to remain the largest market, expanding from approximately USD 0.22 billion in 2025 to USD 0.64 billion by 2035, supported particularly by Florida and Texas. The West is expected to be the fastest-growing region, increasing from approximately USD 0.14 billion to USD 0.42 billion, supported by technology adoption and population growth. The Northeast is expected to rise from approximately USD 0.15 billion to USD 0.40 billion, remaining highly influential in advanced clinical adoption. The Midwest is projected to expand from approximately USD 0.11 billion to USD 0.28 billion, providing stable replacement and recurring imaging demand.

For manufacturers, the most important commercial question is no longer whether OCT resolution can be improved incrementally. The strategic question is which companies can redesign the AMD diagnostic workflow around earlier detection, fewer unnecessary visits, faster image acquisition, reliable quantitative biomarkers, scalable longitudinal review, and more personalized monitoring.

For hospital systems and retina groups, purchasing decisions will increasingly center on total diagnostic productivity. A device that costs more but reduces acquisition time, minimizes rescanning, replaces separate imaging systems, supports multiple retinal conditions, and improves physician review efficiency can produce a stronger economic outcome than a lower-priced standalone scanner.

For investors and market-entry strategists, the most attractive opportunities are concentrated in swept-source OCT, OCT angiography, integrated autofluorescence and multimodal retinal imaging, AI-enabled disease quantification, distributed retinal diagnostics, and home-based OCT monitoring.

The U.S. Age-Related Macular Degeneration Diagnostic Devices Market is therefore transitioning from a conventional ophthalmic capital-equipment category into a connected retinal-disease intelligence ecosystem. Companies capable of combining diagnostic precision, longitudinal analytics, clinical evidence, workflow economics, regulatory execution, and scalable service infrastructure will be best positioned to capture the market’s projected expansion through 2035.

 

TABLE OF CONTENT

1. U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. AMD Diagnostic Device and Retinal Imaging Manufacturers
1.6.2. Optical, Imaging Sensor, Semiconductor and Component Suppliers
1.6.3. Retina Specialty Practices and Retina Care Networks
1.6.4. Hospitals, Academic Medical Centers and Integrated Health Systems
1.6.5. Comprehensive Ophthalmology and Optometry Practices
1.6.6. Ophthalmic Equipment Distributors, Dealers and Procurement Organizations
1.6.7. Payers, FDA, CMS, Clinical Societies and Other Decision-Makers

What this section provides: This section establishes the market boundary, research scope, methodology, forecasting assumptions, device ecosystem, and stakeholder structure used to measure and validate the U.S. Age-Related Macular Degeneration Diagnostic Devices Market.

2. U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. High-Growth Opportunity Areas

What this section provides: This section provides decision-makers with a concise assessment of market size, historical development, 2025 positioning, 2026–2035 growth direction, technology momentum, competitive intensity, and the highest-value AMD diagnostic opportunities.

3. U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Prevalence of Age-Related Macular Degeneration
3.1.2. Rapid Growth of the U.S. Population Aged 65 Years and Older
3.1.3. Increasing Clinical Dependence on Optical Coherence Tomography
3.1.4. Growing Diagnostic Intensity in Neovascular AMD Management
3.1.5. Expansion of Geographic Atrophy Diagnosis and Longitudinal Monitoring
3.1.6. Growing Adoption of Multimodal Retinal Imaging
3.1.7. Increasing Demand for High-Throughput Retina Practice Workflows
3.2. Restraints and Their Impact Analysis
3.2.1. High Capital Cost of Advanced Retinal Imaging Systems
3.2.2. Reimbursement and Medical-Necessity Limitations for Repeated Imaging
3.2.3. Equipment Replacement Cost and Practice Budget Constraints
3.2.4. Retina Specialist and Ophthalmic Technician Workforce Constraints
3.2.5. Interoperability and Multi-Vendor Image Management Challenges
3.3. Opportunities and Their Impact Analysis
3.3.1. Swept-Source OCT Adoption
3.3.2. OCT Angiography Expansion
3.3.3. AI-Assisted AMD Detection and Quantitative Image Analysis
3.3.4. Home OCT and Remote AMD Monitoring
3.3.5. Geographic Atrophy Treatment-Linked Imaging Demand
3.3.6. Community Ophthalmology and Optometry-Based Early Detection
3.4. Challenges and Their Impact Analysis
3.5. Patent & Innovation Analysis, 2021–2025
3.6. AMD Diagnostic Workflow Economics Analysis
3.7. Retina Practice and Hospital Capital Procurement Behavior Analysis

What this section provides: This section analyzes the demographic, clinical, reimbursement, operational, and technology forces shaping AMD diagnostic demand and helps clients identify both growth catalysts and execution risks.

4. U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Impact of Digitalization and Connected Retinal Imaging
4.6. AMD Diagnostic Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.8. CMS Reimbursement and Coverage Landscape
4.9. Import/Export Restrictions & Tariff Impact
4.10. Government Vision Health Initiatives and Screening Programs
4.11. Impact of Escalating Geopolitical and Semiconductor Supply Risks
4.12. Retina Practice and Hospital Value Analysis Decision Framework

What this section provides: This section provides a complete view of the external operating environment, including FDA regulation, CMS reimbursement, pricing, component supply chains, digital adoption, competitive forces, tariffs, and capital-equipment procurement dynamics.

5. U.S. Age-Related Macular Degeneration Diagnostic Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Optical Coherence Tomography Systems
5.1.3. Fundus and Retinal Cameras
5.1.4. Ultra-Widefield and Multimodal Retinal Imaging Systems
5.1.5. Angiography and Fundus Autofluorescence Systems
5.1.6. Home Monitoring and Home OCT Devices

What this section provides: This section identifies the AMD diagnostic device categories expected to generate the greatest revenue contribution, fastest replacement activity, premiumization, and technology-driven growth through 2035.

6. U.S. Age-Related Macular Degeneration Diagnostic Devices Market – By Diagnostic Application

6.1. Overview
6.1.1. Segment Share Analysis, By Diagnostic Application, 2025 & 2035 (%)
6.1.2. Early Detection and Risk Stratification
6.1.3. Dry AMD and Geographic Atrophy Assessment
6.1.4. Neovascular/Wet AMD Diagnosis
6.1.5. Treatment-Response Monitoring
6.1.6. Disease Progression and Longitudinal Surveillance

What this section provides: This section evaluates diagnostic demand across the AMD clinical pathway and identifies where screening, confirmation, treatment monitoring, and progression assessment are expected to generate the strongest device utilization.

7. U.S. Age-Related Macular Degeneration Diagnostic Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Retina Specialty Practices and Retina Care Networks
7.1.3. Hospitals, Health Systems and Academic Medical Centers
7.1.4. Comprehensive Ophthalmology Clinics
7.1.5. Optometry and Vision-Care Practices
7.1.6. Home and Remote Monitoring Settings

What this section provides: This section identifies the customer settings expected to account for AMD diagnostic-device purchasing, imaging utilization, equipment replacement, workflow investment, and remote-monitoring adoption.

8. U.S. Age-Related Macular Degeneration Diagnostic Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Spectral-Domain Optical Coherence Tomography
8.1.3. Swept-Source Optical Coherence Tomography
8.1.4. OCT Angiography
8.1.5. Retinal Photography, Angiography and Autofluorescence Technologies
8.1.6. AI-Enabled and Connected Diagnostic Technologies

What this section provides: This section compares the imaging and software technologies reshaping AMD diagnosis, including conventional OCT, swept-source imaging, OCTA, multimodal retinal visualization, AI analytics, and connected monitoring.

9. U.S. Age-Related Macular Degeneration Diagnostic Devices Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Direct Retina and Ophthalmology Practice Procurement
9.1.3. Hospital and Academic Medical Center Procurement
9.1.4. Integrated Health System and Enterprise Contracts
9.1.5. Ophthalmic Distributors and Specialty Equipment Dealers
9.1.6. Subscription, Service-Based and Remote Monitoring Procurement Models

What this section provides: This section explains how AMD diagnostic systems are purchased across U.S. retina practices, hospitals, integrated provider organizations, specialty distributors, and emerging subscription or monitoring-service models.

10. U.S. Age-Related Macular Degeneration Diagnostic Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional AMD Prevalence, Aging Population and Medicare Population Analysis
10.1.4. Regional Retina Specialist, Ophthalmology Practice and Imaging Infrastructure Analysis
10.1.5. Regional Reimbursement, Technology Adoption and Procurement Dynamics
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region AMD Diagnostic Device Manufacturers, Retina Care Network and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region AMD Diagnostic Device Manufacturers, Retina Care Network and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region AMD Diagnostic Device Manufacturers, Retina Care Network and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region AMD Diagnostic Device Manufacturers, Retina Care Network and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Diagnostic Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed four-region and 50-state analysis to identify AMD prevalence concentrations, aging-population hotspots, retina-care hubs, premium imaging adoption centers, underserved markets, and state-level commercial opportunities.

11. U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players
11.3. Company Profiles
11.3.1. Carl Zeiss Meditec AG
11.3.2. Heidelberg Engineering GmbH
11.3.3. Topcon Healthcare
11.3.4. Optos plc / Nikon Corporation
11.3.5. NIDEK CO., LTD.
11.3.6. Canon Inc.
11.3.7. Kowa Company, Ltd.
11.3.8. Optomed Plc
11.3.9. Revenio Group / iCare
11.3.10. Haag-Streit Group
11.3.11. Visionix
11.3.12. Tomey Corporation
11.3.13. Notal Vision
11.3.14. Eyenuk, Inc.
11.3.15. Remidio Innovative Solutions
11.3.16. Intalight
11.3.17. OcuSciences, Inc.
11.3.18. Phoenix Technology Group
11.3.19. Clarity Medical Systems
11.3.20. Alcon Inc.
11.3.21. Bausch + Lomb Corporation
11.3.22. Essilor Instruments
11.3.23. RetinAI Medical AG

Note: Each company profile will include company overview, AMD and retinal diagnostic portfolio, U.S. positioning, product and technology strategy, installed-base relevance, AI and software capabilities, FDA/regulatory developments, partnerships, product launches, and recent strategic developments.

What this section provides: This section provides competitor benchmarking, market-share visibility, product-platform comparison, innovation positioning, installed-base dynamics, and strategic intelligence on leading and emerging AMD diagnostic technology companies.

12. U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Swept-Source OCT
12.2.2. High-Speed OCT Angiography
12.2.3. AI-Assisted AMD Detection and Quantification
12.2.4. Home OCT and Remote Retinal Monitoring
12.2.5. Multimodal and Ultra-Widefield Retinal Imaging
12.2.6. Cloud-Based Longitudinal Retinal Image Analytics
12.3. Emerging Business Trends
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix

What this section provides: This section prepares clients for changes in imaging technology, remote monitoring, AI adoption, competitive structure, new revenue models, and investment opportunities expected to shape the market through 2035.

13. U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Strategic Recommendations

13.1. Recommendations for AMD Diagnostic Device Manufacturers
13.2. Recommendations for Retina Practices, Hospitals and Health Systems
13.3. Recommendations for Investors and Private Equity Firms
13.4. Recommendations for Ophthalmic Distributors and Channel Partners
13.5. Recommendations for New Entrants and Startups
13.6. U.S. Go-to-Market Strategy Considerations
13.7. Product Positioning and Portfolio Expansion Guidance
13.8. AI, Software and Data Integration Strategy
13.9. Retina Specialist Education and Clinical Evidence Strategy
13.10. State-Level Commercial Prioritization Framework

What this section provides: This section converts market intelligence into actionable recommendations for product strategy, commercial expansion, customer targeting, channel development, investment decisions, clinical evidence generation, and competitive differentiation.

14. U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Legal Disclaimer
14.5. Third-Party Data Disclaimer

What this section provides: This section defines the report’s analytical limitations, forecast boundaries, data-use conditions, third-party information considerations, and legal disclaimers.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Market Definition and Scope
TABLE 3: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Research Methodology Framework
TABLE 4: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Key Assumptions
TABLE 5: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Stakeholder Analysis
TABLE 7: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Market Attractiveness Index
TABLE 10: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Drivers; Impact Analysis
TABLE 14: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Restraints; Impact Analysis
TABLE 15: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Opportunities; Impact Analysis
TABLE 16: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Challenges; Impact Analysis
TABLE 17: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 18: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: AMD Diagnostic Workflow Economics Matrix
TABLE 19: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Retina Practice and Hospital Capital Procurement Behavior Matrix
TABLE 20: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: PESTEL Analysis
TABLE 21: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Porter’s Five Forces Analysis
TABLE 22: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 23: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Value Chain Analysis
TABLE 24: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Supply Chain Analysis
TABLE 25: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Digitalization and Connected Retinal Imaging Impact
TABLE 26: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: AMD Diagnostic Application & Innovation Landscape
TABLE 27: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: FDA Regulatory Framework Analysis
TABLE 28: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 29: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 30: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Government Vision Health Initiatives and Screening Programs
TABLE 31: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Impact of Geopolitical and Semiconductor Supply Risks
TABLE 32: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Retina Practice and Hospital Value Analysis Decision Framework
TABLE 33: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Product Type Snapshot, 2025
TABLE 34: Segment Dashboard; Definition and Scope, by Product Type
TABLE 35: U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 36: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 37: Optical Coherence Tomography Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 38: Fundus and Retinal Cameras Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 39: Ultra-Widefield and Multimodal Retinal Imaging Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 40: Angiography and Fundus Autofluorescence Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 41: Home Monitoring and Home OCT Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 42: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Diagnostic Application Snapshot, 2025
TABLE 43: Segment Dashboard; Definition and Scope, by Diagnostic Application
TABLE 44: U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 45: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Segment Share Analysis, by Diagnostic Application, 2025 & 2035 (%)
TABLE 46: Early Detection and Risk Stratification Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: Dry AMD and Geographic Atrophy Assessment Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: Neovascular/Wet AMD Diagnosis Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: Treatment-Response Monitoring Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: Disease Progression and Longitudinal Surveillance Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: End User Snapshot, 2025
TABLE 52: Segment Dashboard; Definition and Scope, by End User
TABLE 53: U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 54: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 55: Retina Specialty Practices and Retina Care Networks Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: Hospitals, Health Systems and Academic Medical Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: Comprehensive Ophthalmology Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: Optometry and Vision-Care Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: Home and Remote Monitoring Settings Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Technology Type Snapshot, 2025
TABLE 61: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 62: U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 63: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 64: Spectral-Domain Optical Coherence Tomography Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: Swept-Source Optical Coherence Tomography Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: OCT Angiography Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: Retinal Photography, Angiography and Autofluorescence Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: AI-Enabled and Connected Diagnostic Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Procurement Channel Snapshot, 2025
TABLE 70: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 71: U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 72: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 73: Direct Retina and Ophthalmology Practice Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: Hospital and Academic Medical Center Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: Integrated Health System and Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: Ophthalmic Distributors and Specialty Equipment Dealers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: Subscription, Service-Based and Remote Monitoring Procurement Models Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Regional Snapshot, 2025
TABLE 79: Segment Dashboard; Definition and Scope, by Region
TABLE 80: U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 81: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 82: West Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Regional Overview and Trends
TABLE 83: West Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Key Manufacturers, Retina Care Network and Procurement Ecosystem
TABLE 84: West Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 85: West Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 86: West Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 87: West Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 88: West Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 89: West Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 90: California AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 91: California AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 92: California AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 93: California AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 94: California AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 95: Washington AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 96: Washington AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 97: Washington AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 98: Washington AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 99: Washington AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 100: Arizona AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 101: Arizona AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 102: Arizona AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 103: Arizona AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 104: Arizona AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 105: Colorado AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 106: Colorado AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 107: Colorado AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 108: Colorado AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 109: Colorado AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 110: Oregon AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 111: Oregon AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 112: Oregon AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 113: Oregon AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 114: Oregon AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 115: Utah AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 116: Utah AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 117: Utah AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 118: Utah AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 119: Utah AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 120: Nevada AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 121: Nevada AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 122: Nevada AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 123: Nevada AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 124: Nevada AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 125: New Mexico AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 126: New Mexico AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 127: New Mexico AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 128: New Mexico AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 129: New Mexico AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 130: Idaho AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 131: Idaho AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 132: Idaho AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 133: Idaho AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 134: Idaho AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 135: Montana AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 136: Montana AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 137: Montana AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 138: Montana AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 139: Montana AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 140: Wyoming AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 141: Wyoming AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 142: Wyoming AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 143: Wyoming AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 144: Wyoming AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 145: Alaska AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 146: Alaska AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 147: Alaska AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 148: Alaska AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 149: Alaska AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 150: Hawaii AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 151: Hawaii AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 152: Hawaii AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 153: Hawaii AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 154: Hawaii AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 155: Northeast Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Regional Overview and Trends
TABLE 156: Northeast Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Key Manufacturers, Retina Care Network and Procurement Ecosystem
TABLE 157: Northeast Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 158: Northeast Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 159: Northeast Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 160: Northeast Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 161: Northeast Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 162: Northeast Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 163: New York AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 164: New York AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 165: New York AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 166: New York AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 167: New York AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 168: Massachusetts AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 169: Massachusetts AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 170: Massachusetts AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 171: Massachusetts AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 172: Massachusetts AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 173: New Jersey AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 174: New Jersey AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 175: New Jersey AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 176: New Jersey AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 177: New Jersey AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 178: Pennsylvania AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 179: Pennsylvania AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 180: Pennsylvania AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 181: Pennsylvania AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 182: Pennsylvania AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 183: Connecticut AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 184: Connecticut AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 185: Connecticut AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 186: Connecticut AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 187: Connecticut AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 188: Maine AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 189: Maine AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 190: Maine AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 191: Maine AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 192: Maine AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 193: Vermont AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 194: Vermont AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 195: Vermont AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 196: Vermont AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 197: Vermont AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 198: New Hampshire AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 199: New Hampshire AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 200: New Hampshire AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 201: New Hampshire AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 202: New Hampshire AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 203: Rhode Island AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 204: Rhode Island AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 205: Rhode Island AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 206: Rhode Island AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 207: Rhode Island AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 208: Delaware AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 209: Delaware AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 210: Delaware AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 211: Delaware AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 212: Delaware AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 213: South Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Regional Overview and Trends
TABLE 214: South Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Key Manufacturers, Retina Care Network and Procurement Ecosystem
TABLE 215: South Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 216: South Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 217: South Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 218: South Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 219: South Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 220: South Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 221: Texas AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 222: Texas AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 223: Texas AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 224: Texas AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 225: Texas AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 226: Florida AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 227: Florida AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 228: Florida AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 229: Florida AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 230: Florida AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 231: Georgia AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 232: Georgia AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 233: Georgia AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 234: Georgia AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 235: Georgia AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 236: North Carolina AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 237: North Carolina AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 238: North Carolina AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 239: North Carolina AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 240: North Carolina AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 241: Tennessee AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 242: Tennessee AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 243: Tennessee AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 244: Tennessee AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 245: Tennessee AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 246: South Carolina AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 247: South Carolina AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 248: South Carolina AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 249: South Carolina AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 250: South Carolina AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 251: Alabama AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 252: Alabama AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 253: Alabama AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 254: Alabama AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 255: Alabama AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 256: Mississippi AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 257: Mississippi AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 258: Mississippi AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 259: Mississippi AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 260: Mississippi AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 261: Louisiana AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 262: Louisiana AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 263: Louisiana AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 264: Louisiana AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 265: Louisiana AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 266: Arkansas AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 267: Arkansas AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 268: Arkansas AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 269: Arkansas AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 270: Arkansas AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 271: Kentucky AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 272: Kentucky AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 273: Kentucky AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 274: Kentucky AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 275: Kentucky AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 276: Oklahoma AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 277: Oklahoma AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 278: Oklahoma AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 279: Oklahoma AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 280: Oklahoma AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 281: Virginia AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 282: Virginia AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 283: Virginia AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 284: Virginia AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 285: Virginia AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 286: Maryland AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 287: Maryland AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 288: Maryland AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 289: Maryland AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 290: Maryland AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 291: West Virginia AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 292: West Virginia AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 293: West Virginia AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 294: West Virginia AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 295: West Virginia AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 296: Midwest Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Regional Overview and Trends
TABLE 297: Midwest Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Key Manufacturers, Retina Care Network and Procurement Ecosystem
TABLE 298: Midwest Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 299: Midwest Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 300: Midwest Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 301: Midwest Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 302: Midwest Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 303: Midwest Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 304: Illinois AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 305: Illinois AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 306: Illinois AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 307: Illinois AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 308: Illinois AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 309: Ohio AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 310: Ohio AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 311: Ohio AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 312: Ohio AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 313: Ohio AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 314: Michigan AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 315: Michigan AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 316: Michigan AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 317: Michigan AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 318: Michigan AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 319: Minnesota AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 320: Minnesota AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 321: Minnesota AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 322: Minnesota AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 323: Minnesota AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 324: Indiana AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 325: Indiana AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 326: Indiana AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 327: Indiana AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 328: Indiana AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 329: Wisconsin AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 330: Wisconsin AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 331: Wisconsin AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 332: Wisconsin AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 333: Wisconsin AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 334: Missouri AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 335: Missouri AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 336: Missouri AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 337: Missouri AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 338: Missouri AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 339: Iowa AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 340: Iowa AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 341: Iowa AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 342: Iowa AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 343: Iowa AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 344: Kansas AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 345: Kansas AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 346: Kansas AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 347: Kansas AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 348: Kansas AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 349: Nebraska AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 350: Nebraska AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 351: Nebraska AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 352: Nebraska AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 353: Nebraska AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 354: North Dakota AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 355: North Dakota AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 356: North Dakota AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 357: North Dakota AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 358: North Dakota AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 359: South Dakota AMD Diagnostic Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 360: South Dakota AMD Diagnostic Devices Market, by Diagnostic Application, 2021–2035 (US$ Billion)
TABLE 361: South Dakota AMD Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 362: South Dakota AMD Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 363: South Dakota AMD Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 364: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Competitive Landscape Snapshot, 2025
TABLE 365: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Key Company Market Share Analysis, 2025
TABLE 366: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Company Positioning Matrix
TABLE 367: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 368: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 369: Carl Zeiss Meditec AG: Company Profile
TABLE 370: Heidelberg Engineering GmbH: Company Profile
TABLE 371: Topcon Healthcare: Company Profile
TABLE 372: Optos plc / Nikon Corporation: Company Profile
TABLE 373: NIDEK CO., LTD.: Company Profile
TABLE 374: Canon Inc.: Company Profile
TABLE 375: Kowa Company, Ltd.: Company Profile
TABLE 376: Optomed Plc: Company Profile
TABLE 377: Revenio Group / iCare: Company Profile
TABLE 378: Haag-Streit Group: Company Profile
TABLE 379: Visionix: Company Profile
TABLE 380: Tomey Corporation: Company Profile
TABLE 381: Notal Vision: Company Profile
TABLE 382: Eyenuk, Inc.: Company Profile
TABLE 383: Remidio Innovative Solutions: Company Profile
TABLE 384: Intalight: Company Profile
TABLE 385: OcuSciences, Inc.: Company Profile
TABLE 386: Phoenix Technology Group: Company Profile
TABLE 387: Clarity Medical Systems: Company Profile
TABLE 388: Alcon Inc.: Company Profile
TABLE 389: Bausch + Lomb Corporation: Company Profile
TABLE 390: Essilor Instruments: Company Profile
TABLE 391: RetinAI Medical AG: Company Profile
TABLE 392: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 393: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Disruptive Technologies Impact Matrix
TABLE 394: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Emerging Business Trends
TABLE 395: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Business Opportunities for Startups and Existing Players
TABLE 396: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Investment Prioritization Matrix
TABLE 397: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Strategic Recommendations for AMD Diagnostic Device Manufacturers
TABLE 398: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Strategic Recommendations for Retina Practices, Hospitals and Health Systems
TABLE 399: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 400: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Strategic Recommendations for Ophthalmic Distributors and Channel Partners
TABLE 401: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 402: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: U.S. Go-to-Market Strategy Considerations
TABLE 403: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 404: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: AI, Software and Data Integration Strategy
TABLE 405: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Retina Specialist Education and Clinical Evidence Strategy
TABLE 406: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: State-Level Commercial Prioritization Framework
TABLE 407: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Scope Limitation
TABLE 408: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Data Use Limitation
TABLE 409: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Forecasting Limitation
TABLE 410: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Legal Disclaimer
TABLE 411: U.S. Age-Related Macular Degeneration Diagnostic Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Age-Related Macular Degeneration Diagnostic Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Value Chain Analysis
FIGURE 4: Supply Chain Analysis
FIGURE 5: PESTEL Analysis
FIGURE 6: Porter’s Five Forces Analysis
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Market Dynamics
FIGURE 9: AMD Diagnostic Innovation & Patent Landscape, 2021–2025
FIGURE 10: AMD Diagnostic Workflow Economics Framework
FIGURE 11: Retina Practice and Hospital Capital Procurement Decision Framework
FIGURE 12: U.S. Age-Related Macular Degeneration Diagnostic Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 13: U.S. Age-Related Macular Degeneration Diagnostic Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 14: U.S. Age-Related Macular Degeneration Diagnostic Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 15: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 16: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 17: Optical Coherence Tomography Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 18: Fundus and Retinal Cameras Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: Ultra-Widefield and Multimodal Retinal Imaging Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Angiography and Fundus Autofluorescence Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Home Monitoring and Home OCT Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Diagnostic Application Segment Market Share Analysis, 2025 & 2035
FIGURE 23: Diagnostic Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Early Detection and Risk Stratification Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Dry AMD and Geographic Atrophy Assessment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Neovascular/Wet AMD Diagnosis Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Treatment-Response Monitoring Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Disease Progression and Longitudinal Surveillance Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 30: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Retina Specialty Practices and Retina Care Networks Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Hospitals, Health Systems and Academic Medical Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Comprehensive Ophthalmology Clinics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Optometry and Vision-Care Practices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Home and Remote Monitoring Settings Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 37: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Spectral-Domain Optical Coherence Tomography Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Swept-Source Optical Coherence Tomography Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: OCT Angiography Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Retinal Photography, Angiography and Autofluorescence Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: AI-Enabled and Connected Diagnostic Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 44: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Direct Retina and Ophthalmology Practice Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Hospital and Academic Medical Center Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Integrated Health System and Enterprise Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Ophthalmic Distributors and Specialty Equipment Dealers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Subscription, Service-Based and Remote Monitoring Procurement Models Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 51: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: West Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market Share and Leading Players, 2025
FIGURE 53: West Region Market Share Analysis by State, 2025
FIGURE 54: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: California AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Washington AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Arizona AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Colorado AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Oregon AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Utah AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Nevada AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: New Mexico AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Idaho AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Montana AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Wyoming AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Alaska AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Hawaii AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Northeast Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market Share and Leading Players, 2025
FIGURE 69: Northeast Region Market Share Analysis by State, 2025
FIGURE 70: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: New York AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Massachusetts AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: New Jersey AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Pennsylvania AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Connecticut AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Maine AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Vermont AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: New Hampshire AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Rhode Island AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Delaware AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: South Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market Share and Leading Players, 2025
FIGURE 82: South Region Market Share Analysis by State, 2025
FIGURE 83: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Texas AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Florida AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Georgia AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: North Carolina AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Tennessee AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: South Carolina AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Alabama AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Mississippi AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Louisiana AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Arkansas AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Kentucky AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Oklahoma AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Virginia AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Maryland AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: West Virginia AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Midwest Region U.S. Age-Related Macular Degeneration Diagnostic Devices Market Share and Leading Players, 2025
FIGURE 100: Midwest Region Market Share Analysis by State, 2025
FIGURE 101: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Illinois AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Ohio AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Michigan AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Minnesota AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Indiana AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Wisconsin AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Missouri AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Iowa AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Kansas AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Nebraska AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: North Dakota AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: South Dakota AMD Diagnostic Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 115: Company Positioning Matrix
FIGURE 116: Key Player Product Portfolio Benchmarking
FIGURE 117: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 118: AMD Diagnostic Device Innovation Roadmap
FIGURE 119: Swept-Source OCT Adoption Roadmap
FIGURE 120: OCT Angiography Opportunity Map
FIGURE 121: Home OCT and Remote AMD Monitoring Growth Roadmap
FIGURE 122: Future Market Scenario Analysis, 2026–2035
FIGURE 123: Disruptive Technologies Impact Matrix
FIGURE 124: Emerging Business Trends Matrix
FIGURE 125: Investment Prioritization Matrix
FIGURE 126: Strategic Growth Roadmap for U.S. AMD Diagnostic Device Companies
FIGURE 127: Go-to-Market Strategy Framework
FIGURE 128: Product Positioning and Portfolio Expansion Framework
FIGURE 129: Report Scope and Disclaimer Framework